NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-172488 |   Pharmaceuticals and Medical

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

NASH (Non-alcoholic Steatohepatitis) Biomarkers Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET

7.1 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Gilead Sciences, Inc (GILD)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 AstraZeneca

16.3 GENFIT SA

16.4 Boehringer Ingelheim

16.5 Novartis AG

16.6 Novo Nordisk A/S

16.7 Pfizer Inc

16.8 Bristol-Myers Squibb Company

16.9 Allergan Plc

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Major Types Covered
Hepatic fibrosis biomarkers
Apoptosis biomarkers
Serum biomarkers
Others
Oxidative stress biomarkers

Major Downstream Industry Covered
Diagnostic Labs
Pharma & CRO Industry
Hospitals
Academic Research Institutes

Companies

Gilead Sciences, Inc (GILD)
AstraZeneca
GENFIT SA
Boehringer Ingelheim
Novartis AG
Novo Nordisk A/S
Pfizer Inc
Bristol-Myers Squibb Company
Allergan Plc

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.